DETECTION DEVICE, MAGNETIC COMPOSITION, AND MANAGEMENT SYSTEM
A single three-dimensional magnetic sensor system effectively detects orally administered magnetic substances by tracking temporal changes in the magnetic field vector, addressing the bulkiness and cost issues of previous systems.
Patent Information
- Application Number
- JP2020181120
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-31
- Filing Date
- 2020-10-29
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2040-10-29
AI Technical Summary
Existing detection systems for orally administered magnetic substances require multiple sensor components, making them bulky and costly, hindering their widespread use.
A detection device with a single three-dimensional magnetic sensor arranged in multiple directions to measure the magnetic field vector, using temporal changes in the angle of the magnetic field vector to detect the presence of magnetic compositions within the body.
The solution allows for a compact and cost-effective detection of orally administered magnetic substances by accurately tracking their movement within the body, reducing the need for multiple sensors and minimizing environmental interference.
Smart Images

Figure 0007593614000013 
Figure 0007593614000014 
Figure 0007593614000015
Abstract
Description
[Technical field]
[0001] The present invention relates to a detection device for detecting orally administered magnetic compositions, a magnetic composition detected by the detection device, and a management system. [Background technology]
[0002] A detection system for detecting a magnetic body in a human body has been proposed. The detection system described in Patent Document 1 has at least two sensor components. Each sensor component has one to three anisotropic magnetoresistance sensors. In the detection system, for example, a magnetic field vector based on a magnetic body administered orally is measured in each sensor component. Next, the difference (called a vector difference) between the magnetic field vectors measured in each sensor component is calculated. The detection system detects the magnetic body based on the calculated vector difference. In this way, the detection system detects the swallowing of the magnetic body, the passage of the magnetic body through the esophagus, the movement of the magnetic body due to peristalsis during digestion, etc. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] Special Publication No. 2015-500715 Summary of the Invention [Problem to be solved by the invention]
[0004] In the above detection system, at least two sensor components are required to detect a magnetic material. Therefore, if an orally administered magnetic material is to be detected over a wide area of the human body, many sensor components are required. Therefore, there is a problem that it is difficult to reduce the size and cost of the system.
[0005] An object of the present invention is to provide a detection device, a magnetic composition, and a management system that are capable of detecting an orally administered magnetic substance and that can be made small and low-cost. [Means for solving the problem]
[0006] The detection device of the first aspect of the present invention is a detection device that is orally administered into the human body and detects a magnetic composition containing a magnetic material, and is characterized in that it comprises at least one three-dimensional magnetic sensor that arranges magnetic sensors having directional anisotropy in at least three different directions and measures the magnetic field vector formed by the magnetic material contained in the magnetic composition, an acquisition means for acquiring the magnetic field vector measured by the three-dimensional magnetic sensor, and a detection means for detecting the magnetic composition within the human body based on the magnetic field vector acquired by the acquisition means.
[0007] The detection device detects the magnetic composition orally administered into the human body based on the time change of the magnetic field vector measured by the three-dimensional magnetic sensor. In other words, the detection device can detect the magnetic composition using one three-dimensional magnetic sensor. Therefore, the detection device can be made smaller and less expensive.
[0008] In a first embodiment, the acquiring means may acquire a time change in the angle of the magnetic field vector, and the detecting means may detect that the magnetic composition is located within the detection range of the three-dimensional magnetic sensor when the time change in the angle of the magnetic field vector acquired by the acquiring means or a value obtained by dividing the time change in the angle by the magnitude of the time change in the magnetic field vector is greater than a predetermined amount. In this case, the detecting device can detect the magnetic composition when the angle of the magnetic field vector changes with time, for example, in response to the magnetic composition moving within the human body.
[0009] In the first embodiment, the apparatus may include a plurality of the three-dimensional magnetic sensors attached to different positions of the human body, and the detection means may detect the presence of the magnetic composition within the detection range of the three-dimensional magnetic sensor in which the time change of the angle of the magnetic field vector acquired by the acquisition means or the value obtained by dividing the time change of the angle by the magnitude of the time change of the magnetic field vector is greater than the predetermined amount. In this case, the detection device can accurately detect the magnetic composition from a wide range of areas of the human body.
[0010] In a first aspect, the human body is provided with one three-dimensional magnetic sensor, and the acquisition means acquires the magnetic field vector measured by the three-dimensional magnetic sensor in each of M (M is an integer of 2 or more) periods, which are a plurality of periods divided by a predetermined time, and further includes an average calculation means for calculating an average of the magnetic field vectors acquired by the acquisition means in each of the M periods as an average vector, and the detection means may detect the magnetic composition within the human body based on an Nth average vector, which is the average vector of the magnetic field vectors acquired in an Nth period, which is the Nth (N is an integer of 1 or more and M-1 or less) period when the M periods are arranged in chronological order, among the M average vectors calculated by the average calculation means, and an N+1th average vector, which is the average vector of the magnetic field vectors acquired in an N+1th period, which is the N+1th period corresponding to the next period next to the Nth period when the M periods are arranged in chronological order. In this case, the detection device detects the magnetic composition orally administered into the human body based on an average vector, which is an average of the magnetic field vectors measured by the three-dimensional magnetic sensor in each of the multiple periods. That is, the detection device can detect the magnetic composition using one three-dimensional magnetic sensor. Therefore, the detection device can be made smaller and less expensive.
[0011] In the first aspect, the detection device may further include a determination unit for determining the predetermined time, and the average calculation unit may calculate an average vector of the magnetic field vectors acquired by the acquisition unit for each of the predetermined time periods determined by the determination unit. In this case, the detection device may switch the length of the predetermined time period depending on the speed of movement of the human body to which the magnetic sensor is attached.
[0012] In a first embodiment, the detection means may detect the magnetic composition based on at least one of target parameters, which are a first angle between the N-average vector and the N+1-vector, a second angle between the difference vector between the N-average vector and the N+1-vector and the N-average vector, and a value obtained by dividing the first angle or the second angle by the magnitude of the difference vector. In this case, the detection device can detect the magnetic composition, for example, when the magnetic field vector changes in response to the magnetic composition moving inside the human body.
[0013] In the first aspect, the detection means may detect that the magnetic composition is within the detection range of the three-dimensional magnetic sensor when the target parameter satisfies a predetermined condition. In this case, the detection device can detect the position of the magnetic composition with high accuracy.
[0014] In the first aspect, the magnetic sensor may output a voltage proportional to the measured magnetic field, in which case the detection device can detect the magnetic composition based on the voltage output from the magnetic sensor.
[0015] In a first aspect, the apparatus includes an acceleration sensor and a determination means for determining whether the state of the positional change of the human body satisfies a predetermined condition based on the output result of the acceleration sensor, and the acquisition means may acquire the magnetic field vector when the determination means determines that the state of the positional change satisfies the predetermined condition. For example, the detection device acquires the magnetic field vector when the human body is in a calm state based on the output result of the acceleration sensor, and identifies the magnetic composition. In this case, the effect of the positional change of the human body on the measurement result can be suppressed, so that the detection device can accurately detect the magnetic composition in the human body.
[0016] The magnetic composition according to the second aspect of the present invention is a magnetic composition detected by the detection device according to the first aspect, and is orally administered to the human body and contains at least a magnetic material. In this case, the magnetic composition can achieve the same effects as the first aspect. Furthermore, by making it a magnetic composition, it can be easily administered to the human body. Furthermore, it can be detected more accurately than when it is administered in the form of a magnetic material.
[0017] In a second embodiment, the magnetic composition may remain in the stomach for at least one hour after oral administration. The detection device may measure the magnetic field vector intermittently using a three-dimensional magnetic sensor during the period in which the magnetic composition remains in the stomach, thereby reducing the processing load of the detection device and enabling the detection device to be power-saving.
[0018] In a second embodiment, the magnetic composition may be excreted without being broken down in the body when orally administered. In this case, the magnetic composition may be broken down to suppress attenuation of the magnetic vector required for detection by the detection device.
[0019] In the second aspect, the magnetic substance may include iron oxide, which allows the detection device to measure the magnetic field vector with a three-dimensional magnetic sensor with high accuracy.
[0020] In the second aspect, the magnetic material may include at least one of maghemite, magnetite, and epsilon ferric oxide. In this case, the detection device can measure the magnetic field vector with the three-dimensional magnetic sensor with even greater accuracy.
[0021] In a second embodiment, the magnetic composition may further comprise an enteric material, in which case the magnetic composition may be formulated to have a desired behavior in the intestine.
[0022] In a second embodiment, the magnetic composition may further comprise a poorly water-soluble substance, in which case the magnetic composition can be prepared so that its behavior in the intestines is as desired.
[0023] In the second embodiment, the magnetic composition may further contain oil or fat. In this case, the degree to which the magnetic composition absorbs liquid can be reduced, so that the magnetic composition can be appropriately retained in the human body.
[0024] In a second embodiment, the orally administered composition may be a dry-coated tablet having the magnetic composition as a core, or a multi-layer tablet having the magnetic body layered with a substance other than the magnetic body. It may also be a multi-layer tablet having at least one layer of the magnetic composition. The substance other than the magnetic body may contain at least one of a drug substance, an enteric substance, a poorly water-soluble substance, an oil or a lubricant. Alternatively, the orally administered composition may be a capsule filled with a powder, fine grains, granules, or small tablets containing a medicine together with the magnetic composition.
[0025] A management system according to a third aspect of the present invention is a management system for managing the ingestion of pharmaceutical substances, comprising a magnetic composition and a detection device, wherein the detection device is a detection device that is orally administered into the human body and detects the magnetic composition containing a magnetic material, and is equipped with at least one three-dimensional magnetic sensor that measures a magnetic field vector formed by the magnetic material contained in the magnetic composition, an acquisition means that acquires the magnetic field vector measured by the three-dimensional magnetic sensor, and a detection means that detects the magnetic composition within the human body based on the magnetic field vector acquired by the acquisition means, wherein the magnetic composition is orally administered into the human body, contains at least the magnetic material, and is detected by the detection device.
[0026] In a third embodiment, the magnetic composition can be administered together with other orally administered compositions such as food or medicine to confirm that the orally administered composition has been administered to the human body, or can be embedded in the orally administered composition to confirm that the orally administered composition has been administered to the human body.
[0027] In a third embodiment, the orally administered composition may be in a form in which the magnetic composition contains an active ingredient such as a medicine or a specified health food.
[0028] The medication management system of the third aspect can manage the administration of an orally administered composition to the human body using the detection device of the first aspect of the invention and the magnetic composition of the second aspect. [Brief description of the drawings]
[0029] [Figure 1] 1 is a diagram showing an overview and an electrical configuration of a detection device 1. FIG. [Diagram 2] 11 is a flowchart of a first main process. [Diagram 3] 1 is a table showing the measurement results in Example 1. [Figure 4] 13 is a graph showing the change over time of the angle θ. [Diagram 5] 1 is a graph showing the change in value R(N) over time. [Figure 6] 13 is a flowchart of a second main process. [Figure 7] 7 is a flowchart of the second main process, which is a continuation of FIG. [Figure 8] 13 is a flowchart showing a switching process. [Figure 9] 1 is a table showing the composition of each sample in Example 2. [Figure 10] 1 is a table showing the measurement results of the weight loss rate in Example 2. [Figure 11] 1 is a graph showing the measurement results of the weight loss rate in Example 3. [Figure 12] 1 is a table showing the amounts of ingredients used in Example 4. [Figure 13] 1 is a table showing the weight change rate of a tablet in a test liquid in Example 4. [Figure 14] 1 is a table showing the weight change rate of tablets administered to beagle dogs in Example 5. [Figure 15] 11 is a table showing the state of the discharged tablets in Example 5. [Figure 16] 1 is a table showing the amounts of ingredients used in Example 6. [Figure 17]1 is a table showing the amounts of ingredients used in Example 7. [Figure 18] 1 is a table showing the amounts of ingredients in Example 10. [Figure 19] 13 is a graph showing the measurement results of magnetic flux density in Example 10. [Figure 20] 13 is a graph showing the measurement results of magnetic flux density in Example 11. [Figure 21] 13 is a graph showing the measurement results of magnetic flux density in Example 11. [Figure 22] 13 is a graph showing the measurement results of magnetic flux density in Example 12. [Figure 23] 11 is a graph showing a change over time in a value R(N) calculated using a first angle. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] The following description will discuss specific embodiments of the present invention with reference to the drawings. The drawings are used to explain technical features that the present invention may employ, and the configurations of the devices described therein are not intended to be limiting, but are merely illustrative examples.
[0031] <Outline of detection device 1> An overview of the detection device 1 will be described with reference to FIG. 1. The detection device 1 is a device for detecting a magnetic composition 9 administered orally into the human body. The magnetic composition 9 has at least a magnetic material. Details of the magnetic composition 9 will be described later. The detection device 1 measures a magnetic field vector formed by the magnetic material of the magnetic composition 9 orally administered into the body from outside the human body using a three-dimensional magnetic sensor 5, and detects that the magnetic composition 9 is inside the human body. The detection device 1 includes a control circuit unit 2, a power supply unit 31, a display unit 32, sensor heads 6A and 6B (collectively referred to as "sensor head 6"), and an acceleration sensor 7.
[0032] The sensor head 6 is attached to the wear W worn on the human body by a hook-and-loop fastener or the like. In the case of FIG. 1, the sensor head 6 is placed on the front of the human body near the front of the stomach. The sensor heads 6A and 6B are arranged in the left-right direction. The sensor head 6A is arranged on the left side of the left-right center of the human body (the right side as seen from the human body). The sensor head 6B is arranged on the left side of the left-right center of the human body (the left side as seen from the human body). The three-dimensional magnetic sensors 51 and 52 are incorporated in the sensor head 6A. The three-dimensional magnetic sensors 51 and 52 are arranged in the up-down direction. The three-dimensional magnetic sensor 51 is arranged above the three-dimensional magnetic sensor 52. The three-dimensional magnetic sensors 53 and 54 are incorporated in the sensor head 6B. The three-dimensional magnetic sensors 53 and 54 are arranged in the up-down direction. The three-dimensional magnetic sensor 53 is arranged above the three-dimensional magnetic sensor 54. That is, the three-dimensional magnetic sensors 51 to 54 are attached to different positions on the human body. The three-dimensional magnetic sensors 51 to 54 are collectively referred to as the "three-dimensional magnetic sensor 5."
[0033] The three-dimensional magnetic sensor 5 has three magnetic impedance sensors (MI sensors) having directional anisotropy arranged in three mutually orthogonal axial directions (X-axis, Y-axis, and Z-axis). The X-axis, Y-axis, and Z-axis directions correspond, for example, to the left-right direction, the front-back direction, and the up-down direction, respectively. Each MI sensor can measure the strength of a specific directional component (X-axis component, Y-axis component, and Z-axis component) of the magnetic field vector formed by the magnetic material contained in the magnetic composition 9. Having directional anisotropy means that each MI sensor can measure only the strength of a specific directional component of the magnetic field vector. For example, the three MI sensors include an X-axis sensor capable of measuring the X-axis component of the magnetic field vector, a Y-axis sensor capable of measuring the Y-axis component of the magnetic field vector, and a Z-axis sensor capable of measuring the Z-axis component of the magnetic field vector.
[0034] The three-dimensional magnetic sensor 5 is connected to the control circuit unit 2 described below via a cable C1. The three-dimensional magnetic sensor 5 outputs to the control circuit unit 2 voltage signals proportional to the magnetic field vectors measured by each of the X-axis sensor, the Y-axis sensor, and the Z-axis sensor.
[0035] When a magnetic field vector formed by the magnetic material of the magnetic composition 9 is measured by the three-dimensional magnetic sensor 5, the range in which a magnetic field vector of a predetermined magnitude or more can be detected is called the detection range 50A. In Fig. 1, the detection ranges 50A corresponding to the three-dimensional magnetic sensors 51, 52, 53, and 54, respectively, are shown as detection ranges 51A, 52A, 53A, and 54A.
[0036] The control circuit unit 2 is disposed at a position separated from the human body. The control circuit unit 2 acquires a voltage signal output from the three-dimensional magnetic sensor 5 via a cable C1. The control circuit unit 2 determines whether or not the magnetic composition 9 has been detected within the human body based on the magnetic field vector indicated by the acquired voltage signal. The power supply unit 31 is connected to the control circuit unit 2 via a cable C2 and supplies driving power to the control circuit unit 2. The display unit 32 is connected to the control circuit unit 2 via a cable C3. The display unit 32 has an LCD and displays characters and patterns on the LCD in response to instructions from the control circuit unit 2. The control circuit unit 2, the power supply unit 31, and the display unit 32 may be directly attached to the human body together with the sensor head 6. The power supply unit 31 and the display unit 32 may be integrated with the control circuit unit 2.
[0037] The acceleration sensor 7 is attached to the garment W worn on the human body by a hook-and-loop fastener or the like. The acceleration sensor 7 is connected to the control circuit unit 2 via a cable C4. The acceleration sensor 7 measures acceleration whose magnitude corresponds to the movement of the garment W linked to the human body. The acceleration sensor 7 outputs a signal indicating the magnitude of the measured acceleration to the control circuit unit 2. The control circuit unit 2 acquires the signal output from the acceleration sensor 7 via the cable C4. The control circuit unit 2 determines the state of positional change of the human body wearing the garment W based on the magnitude of acceleration indicated by the acquired signal.
[0038] <Electrical configuration> As shown in FIG. 1, the control circuit section 2 has a CPU 21, a storage section 22, an interface (I / F) circuit 23, and an input section 24. The CPU 21 controls the overall operation of the detection device 1. The storage section 22 stores programs executed by the CPU 21, measured magnetic field vectors, setting parameters (e.g., a predetermined time T described later), and the like. The I / F circuit 23 is an interface element for connecting to external devices via cables C1 to C4. The input section 24 accepts input operations to the control circuit section 2. The CPU 21, the storage section 22, the I / F circuit 23, and the input section 24 are electrically connected to each other.
[0039] The three-dimensional magnetic sensor 5 is electrically connected to the CPU 21 via a cable C1 and an I / F circuit 23. The power supply unit 31 is connected to the control circuit unit 2 via a cable C2, and supplies driving power to the CPU 21, the storage unit 22, and the I / F circuit 23. The display unit 32 is electrically connected to the CPU 21 via a cable C2 and the I / F circuit 23. The acceleration sensor 7 is electrically connected to the CPU 21 via a cable C4 and the I / F circuit 23.
[0040] First Embodiment <Detection method> The X-axis, Y-axis, and Z-axis components of the magnetic field vector measured by the three-dimensional magnetic sensor 5 are denoted as Bx, By, and Bz. Bx, By, and Bz correspond to the magnetic field vector measured by the X-axis sensor, the Y-axis sensor, and the Z-axis sensor of the three-dimensional magnetic sensor 5, respectively. The magnetic field vector measured by the three-dimensional magnetic sensor 5 is denoted as B or B(Bx, By, Bz). The unit of magnitude of the magnetic field vectors B, Bx, By, and Bz is nT.
[0041] The time-differentiated values B' (B'x, B'y, B'z) of the magnetic field vector B (Bx, By, Bz) are respectively expressed by the following equation (1).
number
number
[0042] The time change θ' obtained by time-differentiating the angle θ (rad) of the magnetic field vector B satisfies the relationship of the following equation (3). Here, |B| indicates the magnitude of the magnetic field vector B. |B'| indicates the magnitude of the time change B' of the magnetic field vector B.
number
[0043] Define the value R', which indicates the time change θ' as a ratio per unit amount of |B'|. The value R' corresponds to the value obtained by dividing the time change θ' by |B'|, and satisfies the relationship of the following formula (4).
number
[0044] Here, when the magnetic composition 9 orally administered to the human body is present in the stomach, the magnetic composition 9 also moves in response to the peristaltic movement of the stomach. At this time, the direction of the magnetic field vector formed by the magnetic body fluctuates with the period of the peristaltic movement. Therefore, the CPU 21 of the control circuit unit 2 determines that the magnetic composition 9 is present within the detection range 50A of the three-dimensional magnetic sensor 5 when R' is -0.02 rad or less or 0.02 rad or more (R'≦-0.02 rad or 0.02 rad≦R') and |B'| is 50 nT or more (50 nT≦|B'|). In other words, R' being -0.02 rad or less or 0.02 rad or more corresponds to |R'| being 0.02 rad or more. Also, it indicates that the value obtained by dividing the time change θ' of the angle of the magnetic field vector B formed by the magnetic composition 9 by the magnitude |B'| of the time change B' of the magnetic field vector is greater than a predetermined amount. The reason for not directly determining the time change θ' but using the value R' divided by |B'| is to eliminate the influence of environmental magnetic fields other than the magnetic field formed by the magnetic material of the magnetic composition 9. Also, by setting a lower limit for |B'|, the influence of noise components in the signal output from the three-dimensional magnetic sensor 5 is eliminated. Note that the above ±0.02 rad (i.e. ±1.1 deg) is an example of a threshold value, and other values may be used.
[0045] <First main process> A first main process executed by the CPU 21 in the first embodiment will be described with reference to Fig. 2. The CPU 21 executes the first main process at a predetermined sampling period (for example, 0.1005 s) based on a program stored in the storage unit 22.
[0046] When the sampling period arrives, the CPU 21 acquires a signal output from the acceleration sensor 7 and identifies the magnitude of the acceleration. The CPU 21 compares the identified magnitude of the acceleration with a predetermined threshold. If the magnitude of the acceleration is greater than the predetermined threshold, the CPU 21 determines that the positional fluctuation of the human body to which the acceleration sensor 7 is attached via the wear W is large (S11: NO). In this case, the CPU 21 ends the first main process. On the other hand, if the magnitude of the acceleration is equal to or less than the predetermined threshold, the CPU 21 determines that the positional fluctuation of the human body is small (S11: YES). In this case, the CPU 21 advances the process to S13.
[0047] The CPU 21 acquires signals output by the three-dimensional magnetic sensors 51-54, and identifies the magnetic field vector B (Bx, By, Bz) measured by each of the three-dimensional magnetic sensors 51-54 (S13). The CPU 21 calculates a time change θ' of the identified magnetic field vector B for each of the three-dimensional magnetic sensors 51-54 based on equations (1)-(3) (S15). Furthermore, the CPU 21 calculates a value R' for each of the three-dimensional magnetic sensors 51-54 based on equation (4) (S17).
[0048] The CPU 21 executes the following process for each of the three-dimensional magnetic sensors 51 to 54. The CPU 21 judges whether |B'| is 50nT or more for each of the three-dimensional magnetic sensors 51 to 54 (S19). When the CPU 21 judges that |B'| is smaller than 50nT (S19: NO), the process proceeds to S27. When the CPU 21 judges that |B'| is 50nT or more (S19: YES), the CPU 21 judges whether |R'| is 0.02rad or more (S21). When the CPU 21 judges that |R'| is 0.02rad or more (S21: YES), the time change θ' of the angle of the magnetic field vector B is larger than a predetermined amount, and therefore the CPU 21 judges that the magnetic composition 9 is present in the human body at a position within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S23). The CPU 21 proceeds to S27. Note that the above 50nT is an example of a threshold value, and other values may be used.
[0049] When the CPU 21 determines that |R'| is less than 0.02 rad (S21: NO), it determines that there is no magnetic composition 9 in the human body at a position within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S25). The CPU 21 advances the process to S27.
[0050] The CPU 21 determines whether the processes of S19, S21, S23, and S25 have been performed for all of the three-dimensional magnetic sensors 51 to 54 (S27). If the CPU 21 determines that the processes have not been performed for all of the three-dimensional magnetic sensors 51 to 54 (S27: NO), the process returns to S19. The CPU 21 repeats the processes of S19, S21, S23, and S25 while changing the target three-dimensional magnetic sensor 5 until all of the three-dimensional magnetic sensors 51 to 54 have been processed. If the CPU 21 determines that the processes have been performed for all of the three-dimensional magnetic sensors 51 to 54 (S27: YES), the process proceeds to S29.
[0051] The CPU 21 displays on the display unit 32 a notification image indicating whether or not the magnetic composition 9 is present in the detection ranges 51A-54A for each of the three-dimensional magnetic sensors 51-54 (S29). The CPU 21 ends the first main process.
[0052] <Example 1> The results of an experiment conducted using the detection device 1 will be described. The sensor heads 6A and 6B shown in FIG. 1 were used. The experiment was conducted for 10 minutes each for the cases where the magnetic composition 9 was orally administered and where it was not. During the 10-minute experimental period, the detection device 1 acquired the signal output from the three-dimensional magnetic sensor 5 at a sampling period (0.1005 s). Then, whether or not the magnetic composition 9 was present within the human body within the detection range 50A of each of the three-dimensional magnetic sensors 51 to 54 was determined a total of 6000 times for each sampling period.
[0053] FIG. 3 shows the number of times that the magnetic composition 9 was determined to be present within the detection range 50A by each of the three-dimensional magnetic sensors 51 to 54. The number of times that the magnetic composition 9 was determined to be present within the human body before administration of the magnetic composition 9 was within the range of 0 to 2 times for each of the three-dimensional magnetic sensors 51 to 54. In contrast, for the three-dimensional magnetic sensors 51 and 52, the number of times that the magnetic composition 9 was determined to be present within the human body after administration of the magnetic composition 9 was 10 or more times, which was a significant increase compared to before administration. From this result, it was found that the magnetic composition 9 can be detected to be present within the detection range 51A of the three-dimensional magnetic sensor 51 and the detection range 52A of the three-dimensional magnetic sensor 52 after administration of the magnetic composition 9. From the above results, it was found that the detection device 1 can determine whether or not the magnetic composition 9 is present within the human body.
[0054] On the other hand, for the three-dimensional magnetic sensors 53 and 54, the number of times that the magnetic composition 9 was determined to be present in the human body after administration of the magnetic composition 9 was one or two, which was almost unchanged from before administration. From this result, it is estimated that the magnetic composition 9 after administration is highly likely to be present in the area where the three-dimensional magnetic sensors 51 and 52 are attached, in other words, the area on the left side of the center in the left-right direction of the human body, and is less likely to be present in the area on the right side. From the above results, it was found that the detection device 1 can precisely identify the area where the magnetic composition 9 is present in the human body by using multiple three-dimensional magnetic sensors 5.
[0055] <Actions and Effects of the First Embodiment> The detection device 1 calculates the time change of the magnetic field vector B measured by the three-dimensional magnetic sensor 5 (S15), and detects the magnetic composition 9 orally administered into the human body based on the calculation result (S21). In this case, the detection device 1 is capable of detecting the magnetic composition 9 using one three-dimensional magnetic sensor 5. Therefore, the detection device 1 can be made smaller and less expensive than when multiple three-dimensional magnetic sensors must be used to detect the magnetic composition 9.
[0056] The detection device 1 calculates the time change θ' of the angle θ of the magnetic field vector B (S15). If the absolute value |R'| of the value R' obtained by dividing the time change θ' of the angle θ of the magnetic field vector B by the magnitude |B'| of the time change of the magnetic field vector B is greater than a predetermined amount 0.02 (S21: YES), the detection device 1 detects that the magnetic composition 9 is present at a position within the detection range 50A of the three-dimensional magnetic sensor 5 (S23). In this case, the detection device 1 can detect the magnetic composition 9 when the angle θ of the magnetic field vector B changes over time in response to the magnetic composition 9 moving within the human body. Specifically, for example, when the magnetic composition 9 moves within the human body in response to the peristaltic movement (about 0.05 Hz) of the stomach after being orally administered, the angle θ of the magnetic field vector B changes over time. Therefore, the detection device 1 can appropriately detect that the magnetic composition 9 is in the stomach based on the time change θ' of the angle θ of the magnetic field vector B.
[0057] The detection device 1 has three-dimensional magnetic sensors 51-54 attached to different positions on the human body. When it is determined that |B'| is 50 nT or more (S19: YES) and the value |R'| is greater than 0.02 rad (S21: YES) for at least any of the three-dimensional magnetic sensors 51-54, the detection device 1 detects that the magnetic composition 9 is present within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S23). In this case, the detection device 1 can accurately detect the magnetic composition 9 from a wide area of the human body by attaching the three-dimensional magnetic sensors 51-54 to a wide area of the human body. Furthermore, the detection device 1 can more accurately identify the position of the human body where the magnetic composition 9 is present.
[0058] The detection device 1 includes an acceleration sensor 7. The detection device 1 determines whether the positional fluctuation of the human body is small based on the output result of the acceleration sensor 7 (S11). When the detection device 1 determines that the positional fluctuation of the human body is small (S11: YES), it calculates the change θ' over time in the angle θ of the magnetic field vector B to detect the magnetic composition 9. In this case, the detection device 1 can obtain the change θ' over time in the angle θ of the magnetic field vector B when the human body is in a calm state, and detect the magnetic composition 9. Therefore, the detection device 1 can minimize the effect of the positional fluctuation of the human body on the measurement result, and can accurately detect the magnetic composition 9 inside the human body.
[0059] <Special Notes on the First Embodiment> The CPU 21 performing the process of S15 is an example of the "acquiring means" of the present invention. The CPU 21 performing the process of S21 is an example of the "detecting means" of the present invention. The CPU 21 performing the process of S11 is an example of the "determining means" of the present invention.
[0060] <Second embodiment> <Detection method> Magnetic field vector B (Bx, By, Bz) is measured n times (n is an integer) for a plurality of periods (first period, second period,...N-1th period, Nth period, N+1th period...) (N is an integer) divided by a predetermined time T. Next, the average of the n magnetic field vectors measured in each period is calculated. The calculated magnetic field vector is called an average vector and is represented as A or A(Ax, Ay, Az). Ax, Ay, Az indicate the X-axis, Y-axis, and Z-axis components of the calculated average vector. Ax, Ay, and Az are expressed by the following formula (5). Bx(i), By(i), and Bz(i) correspond to the X-axis, Y-axis, and Z-axis components of the magnetic field vector B measured in the i-th direction among the n magnetic field vectors B measured in each period.
number
[0061] A difference vector is calculated between the Nth average vector A(N) calculated based on the magnetic field vector B measured in the Nth period, and the N+1th average vector A(N+1) calculated based on the magnetic field vector B measured in the N+1th period, which is the period following the Nth period. The calculated difference vector is denoted as the Nth difference vector ΔA(N). The components of the Nth difference vector ΔA(N) in the X-axis direction, Y-axis direction, and Z-axis direction are denoted as ΔAx(N), ΔAy(N), and ΔAz(N). ΔAx(N), ΔAy(N), and ΔAz(N) are expressed by the following equation (6).
number
[0062] The angle θ(N) between the N-th average vector A(N) and the N-th difference vector ΔA(N) satisfies the relationship of the following formula (7).
number
number
number
[0063] When a change in position of the magnetic composition 9 occurs near the three-dimensional magnetic sensor 5, the angle θ(N) changes according to the orientation of the magnetic poles of the magnetic composition 9 and the direction of movement. The angle θ(N) at this time can take any value between -π and +π [rad]. However, when noise such as a rotation in a uniform environmental magnetic field due to body movement acts on the three-dimensional magnetic sensor 5, the angle θ(N) takes a value in a very narrow range centered on π / 2 [rad].
[0064] Therefore, the CPU 21 of the control circuit unit 2 determines whether the angle obtained by subtracting π / 2 [rad] from the angle θ(N) is greater than a predetermined angle threshold θth. The angle obtained by subtracting π / 2 [rad] from the angle θ(N) is represented as φ(N) (see equation (10)).
number
[0065] Also, random noise due to fluctuations in the environmental magnetic field around the three-dimensional magnetic sensor 5 may have an effect. The angle θ(N) in this case can also take any value between -π and +π [rad]. However, in this case, the absolute value of the Nth difference vector ΔA(N) is relatively small compared to when a position change occurs in the vicinity of the three-dimensional magnetic sensor 5.
[0066] For this reason, the CPU 21 of the control circuit unit 2 determines whether the absolute value of the Nth difference vector ΔA(N) is greater than a predetermined magnitude threshold value Mth (see equation (11)).
number
[0067] As described above, by using equations (10) and (11), the CPU 21 of the control circuit unit 2 can accurately detect a change in the position of the magnetic composition 9 in the vicinity of the three-dimensional magnetic sensor 5, even in the presence of random noise due to body movement noise or fluctuations in the environmental magnetic field.
[0068] The CPU 21 of the control circuit section 2 determines whether or not the magnetic composition 9 is present in the vicinity of the three-dimensional magnetic sensor 5 by the following method. Here, when the magnetic composition 9 orally administered to the human body is present in the stomach, the magnetic composition 9 also moves in response to the peristaltic movement of the stomach. At this time, the direction of the magnetic field vector formed by the magnetic material of the magnetic composition 9 varies with the period of the peristaltic movement. In response to this, the CPU 21 calculates a value R(N) obtained by dividing the angle φ(N) by the magnitude |ΔA(N)| of the difference vector based on the following formula (12).
number
[0069] The CPU 21 determines that the magnetic composition 9 is moving with a period of peristalsis when R(N) is -0.02 rad or less or 0.02 rad or more (R(N)≦-0.02 rad or 0.02 rad≦R(N)) and |ΔA(N)| is 50 nT or more (50 nT≦|ΔA(N)|). In this case, the CPU 21 determines that the magnetic composition 9 is within the detection range 50A of the three-dimensional magnetic sensor 5.
[0070] In addition, R(N) being -0.02 [rad] or less or 0.02 [rad] or more corresponds to |R(N)| being 0.02 [rad] or more. It also indicates that the value obtained by dividing the angle φ(N) by the magnitude of the difference vector |ΔA(N)| is greater than a predetermined amount (50nT).
[0071] The reason for not directly determining the angle φ(N) but using the value R(N) obtained by dividing it by |ΔA(N)| is to eliminate the influence of environmental magnetic fields other than the magnetic field formed by the magnetic body of the magnetic composition 9. Also, by setting a lower limit for |ΔA(N)|, the influence of noise components in the voltage signal output from the three-dimensional magnetic sensor 5 is eliminated. Note that the above ±0.02 [rad] (i.e. ±1.1 [deg]) and 50 nT are examples of threshold values, and other values may be used.
[0072] In addition, it is generally known that the magnetic composition 9 in the stomach moves periodically at 0.5 Hz or less. The magnetic field vector B (Bx, By, Bz) measured by the three-dimensional magnetic sensor 5 includes a relatively high-frequency random noise signal received from various external environments in addition to the slowly cyclic voltage signal of the magnetic composition 9. For this reason, the value B' (X-axis component B'x, Y-axis component B'y, Z-axis component B'z) obtained by time-differentiating the magnetic field vector B is easily affected by these signals. Therefore, when the value B' is used to detect the position of the magnetic composition 9, the accuracy of the position detection may decrease. In contrast, as described above, the average vector A is calculated for the measured magnetic field vector B (Bx, By, Bz) for each of a plurality of periods, and the average vector A is used as a parameter when determining the position detection of the magnetic composition 9, which is effective in removing high-frequency and random noise.
[0073] For example, FIG. 4 is a graph showing the angle θ calculated using formula (9) based on the magnetic field vector B measured by the three-dimensional magnetic sensor 5. FIG. 5 is a graph showing the value R(N) calculated using formula (12) based on the magnetic field vector B measured by the three-dimensional magnetic sensor 5. The horizontal axis of each graph shows time (seconds). The vertical axis of FIG. 4 shows the angle θ [deg], and the vertical axis of FIG. 5 shows the value R(N). FIG. 4 and FIG. 5 show the results of an experiment conducted on an obese subject. FIG. 4(A)-(C) and FIG. 5(A)-(C) show the results before the magnetic composition 9 was orally administered, and FIG. 4(D)-(F) and FIG. 5(D)-(F) show the results after the magnetic composition 9 was taken. FIG. 4(A), FIG. 4(D), FIG. 5(A), and FIG. 5(D) show the results when the predetermined time T for calculating the average vector A is set to 0.5 s. Figures 4(B), 4(E), 5(B), and 5(E) show the results when the predetermined time T is 1.0 s. Figures 4(C), 4(F), 5(C), and 5(F) show the results when the predetermined time T is 2.0 s. Note that the application of equations (9) and (12) is performed after high-frequency noise is removed from the magnetic field vector B measured by the three-dimensional magnetic sensor 5.
[0074] 4 and 5, it is clear that the degree of change in the angle θ and the value R(N) before and after oral administration becomes clear. It is also clear that it is effective to change the length of the predetermined time T according to the speed of movement of the human body wearing the three-dimensional magnetic sensor 5.
[0075] <Second main process> The second main processing executed by the CPU 21 in the second embodiment will be described with reference to Fig. 6. The CPU 21 executes the second main processing at a predetermined sample period (e.g., 0.1005 s) based on a program stored in the storage unit 22. When the second main processing is started for the first time, the variable m stored in the storage unit 22 is set to 1.
[0076] When the sampling period arrives, the CPU 21 acquires a voltage signal output from the acceleration sensor 7 and identifies the magnitude of the acceleration. The CPU 21 compares the identified magnitude of the acceleration with a predetermined threshold. If the magnitude of the acceleration is greater than the predetermined threshold, the CPU 21 determines that the positional fluctuation of the human body to which the acceleration sensor 7 is attached via the wear W is large (S31: NO). In this case, the CPU 21 ends the second main process. On the other hand, if the magnitude of the acceleration is equal to or less than the predetermined threshold, the CPU 21 determines that the positional fluctuation of the human body is small (S31: YES). In this case, the CPU 21 advances the process to S33.
[0077] The CPU 21 acquires the voltage signals output by the three-dimensional magnetic sensors 51-54, and identifies the magnetic field vector B (Bx, By, Bz) measured by each of the three-dimensional magnetic sensors 51-54 (S33). The CPU 21 stores the identified magnetic field vector B in the storage unit 22 as a magnetic field vector measured in the m-th (=1) period (S35). The CPU 21 reads and acquires the predetermined time T stored in the storage unit 22. The CPU 21 determines whether the predetermined time T has elapsed since the end of the m-1-th period (S37). Note that, when the variable m is set to 1, the CPU 21 determines whether the predetermined time T has elapsed since the second main process was initially started. When the CPU 21 determines that the predetermined time T has not elapsed (S37: NO), the second main process ends.
[0078] When the second main process is repeatedly started at a sample period and a predetermined time T has elapsed (S37: YES), the CPU 21 reads out and acquires the magnetic field vector B measured in the m-th (=1) period from the storage unit 22 (S39). The CPU 21 calculates the m-th (=1) average vector A(m(=1)) based on the acquired magnetic field vector B (S41). The CPU 21 stores the calculated first average vector A(1) in the storage unit 22 (S43).
[0079] The CPU 21 determines whether the variable m is equal to or greater than 2 (S45). If the variable m is 1 (S45: NO), the CPU 21 advances the process to S53. The CPU 21 updates the variable m by adding 1 (S53), and ends the second main process.
[0080] Based on the updated variable m (=2), the second main process is repeatedly started at a sample period. If the predetermined time T has elapsed (S37: YES), the CPU 21 reads out and acquires the magnetic field vector B measured in the m (=2) period from the storage unit 22 (S39). The CPU 21 calculates the m (=2) average vector A (m (=2)) based on the acquired magnetic field vector B (S41). The CPU 21 stores the calculated second average vector A (2) in the storage unit 22 (S43). The CPU 21 determines whether the variable m is 2 or more (S45). If the CPU 21 determines that the variable m is 2 or more (S45: YES), the process proceeds to S47.
[0081] The CPU 21 calculates a first difference vector ΔA(1) by applying equation (6) based on the first average vector A(1) stored in the storage unit 22 by the previous process of S43 and the second average vector A(2) stored in the storage unit 22 by the current process of S43 (S47). The CPU 21 applies equations (8) and (9) to the calculated first difference vector ΔA(1) to calculate an angle θ(1) (S49). The CPU 21 subtracts π / 2 [rad] from the calculated angle θ(1) to further calculate an angle φ(1) (S51). The CPU 21 advances the process to S71 (see FIG. 7).
[0082] 7, the CPU 21 determines whether the angle φ(1) calculated by the process of S51 (see FIG. 6) is greater than the angle threshold value θth (S71, see formula (10)). If the CPU 21 determines that the angle φ(1) is greater than the angle threshold value θth (S71: YES), there is a possibility that noise accompanying the rotation of the three-dimensional magnetic sensor 5 has been measured, and therefore the process proceeds to S83.
[0083] When the CPU 21 determines that the angle φ is equal to or smaller than the angle threshold θth (S71: NO), the CPU 21 determines whether the absolute value of the first difference vector ΔA(1) is greater than the magnitude threshold Mth (S73, see formula (11)). When the CPU 21 determines that the absolute value of the first difference vector ΔA(1) is greater than the magnitude threshold Mth (S73: YES), there is a possibility that noise due to fluctuations in the environmental magnetic field around the three-dimensional magnetic sensor 5 has been measured, and therefore the process proceeds to S83.
[0084] When the absolute value of the first difference vector ΔA(1) is equal to or smaller than the magnitude threshold value Mth (S73: NO), the CPU 21 calculates a value R(1) by dividing the angle φ(1) by the magnitude |ΔA(1)| of the difference vector based on the formula (12) (S75). The CPU 21 determines whether the absolute value |R(1)| of the calculated value R(1) is equal to or larger than 0.02 rad (S77). When the CPU 21 determines that |R(1)| is equal to or larger than 0.02 rad (S77: YES), it determines that the magnetic composition 9 is present in the human body at a position within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S79). The CPU 21 advances the process to S83.
[0085] When the CPU 21 determines that |R(1)| is smaller than 0.02 rad (S77: NO), it determines that there is no magnetic composition 9 in the human body at a position within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S81). The CPU 21 advances the process to S83.
[0086] CPU 21 determines whether the processes of S39 (see FIG. 5) to S81 have been executed for all three-dimensional magnetic sensors 51 to 54 (S83). If CPU 21 determines that the processes have not been executed for all three-dimensional magnetic sensors 51 to 54 (S83: NO), CPU 21 returns the process to S39 (see FIG. 6). CPU 21 repeats the processes of S39 to S81 while changing the target three-dimensional magnetic sensor 5 until all three-dimensional magnetic sensors 51 to 54 have been processed. If CPU 21 determines that the processes have been executed for all three-dimensional magnetic sensors 51 to 54 (S83: YES), CPU 21 advances the process to S85.
[0087] The CPU 21 displays on the display unit 32 a notification image indicating whether or not the magnetic composition 9 is present in the detection ranges 51A-54A for each of the three-dimensional magnetic sensors 51-54 (S85). The CPU 21 ends the second main process.
[0088] The CPU 21 repeatedly executes the above process while updating the variable m to 1, 2, ..., N, N+1... For example, when the variable m is N+1, the CPU 21 applies the formula (6) based on the N-th average vector A(N) and the N+1-th average vector A(N+1) to calculate the N-th difference vector ΔA(N) (S47). The CPU 21 further calculates the angle θ(N) and the angle φ(N) based on the N-th difference vector ΔA(N) (S49, S51). When the angle φ(N) is equal to or smaller than the angle threshold θth (S71: NO), the absolute value of the N-th difference vector ΔA(N) is equal to or smaller than the magnitude threshold Mth (S73: NO), and the absolute value |R(N)| of the value R(N) is equal to or larger than 0.02 rad (S77: YES), the CPU 21 determines that the magnetic composition 9 is present in the human body at a position within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S79).
[0089] <Decision process> The determination process will be described with reference to Fig. 8. The determination process is started by the CPU 21 reading and executing a program stored in the storage unit 22 when an input operation to the input unit 24 is detected.
[0090] The CPU 21 determines whether an input operation for inputting the predetermined time T has been performed via the input unit 24 (S91). When the CPU 21 determines that an input operation for inputting the predetermined time T has been performed via the input unit 24 (S91: YES), the CPU 21 determines the predetermined time T inputted via the input unit 24 as the predetermined time T to be stored in the storage unit 22, and stores the predetermined time T in the storage unit 22 (S93). The CPU 21 ends the determination process. On the other hand, when the CPU 21 determines that an input operation for inputting the predetermined time T has not been performed via the input unit 24 (S91: NO), the CPU 21 ends the determination process. In addition, in the process of S37 of the second main process (see FIG. 6), the CPU 21 determines whether the predetermined time T has elapsed based on the predetermined time T changed in the determination process.
[0091] <Actions and Effects of the Second Embodiment> The detection device 1 calculates an average vector A, which is an average of the magnetic field vectors B measured by the three-dimensional magnetic sensor 5 in each of a plurality of time periods (S41), and detects the magnetic composition 9 to be orally administered into the human body based on the calculated average vector A (S79). In this case, the detection device 1 is capable of detecting the magnetic composition 9 using one three-dimensional magnetic sensor 5. Therefore, the detection device 1 can be made smaller and less expensive than when a plurality of three-dimensional magnetic sensors must be used to detect the magnetic composition 9.
[0092] When an input operation of the predetermined time T is performed via the input unit 24 (S91: YES), the detection device 1 determines the inputted predetermined time T as the predetermined time T stored in the storage unit 22. The detection device 1 acquires a magnetic field vector B in each of a plurality of periods divided by the determined predetermined time T, and calculates an average vector A (S41). In this case, the detection device 1 can switch the length of the predetermined time T according to the speed of the movement of the human body to which the three-dimensional magnetic sensor 5 is attached. The movement of the human body is characterized by a periodic pulse frequency of 1 Hz, a breathing frequency of 0.5 Hz, a gastric peristaltic frequency of 0.05 Hz, etc. For example, when the predetermined time T of 1 second is determined, the vibration noise caused by the 1 Hz pulse is averaged and attenuated. On the other hand, the movement of the magnetic composition 9 associated with breathing and gastric peristaltic movement is slower than that, and therefore is not attenuated. Therefore, by appropriately determining the predetermined time T, the signal caused by the magnetic composition 9 and the noise can be appropriately separated.
[0093] The detection device 1 calculates the N-th difference vector ΔA(N) between the N-th average vector A(N) and the N+1-th average vector A(N+1) (S47). Furthermore, the detection device 1 further calculates the angle θ(N) between the N-th difference vector ΔA(N) and the N-th average vector A(N), and the angle φ(N) obtained by subtracting π / 2 [rad] from the angle θ(N) (S49, S51). The detection device determines whether the magnetic composition 9 is present within the detection range 50A of the three-dimensional magnetic sensor 5 based on the value R(N) obtained by dividing the calculated angle φ(N) by the magnitude |ΔA(N)| of the N-th average vector (S77). In this case, the detection device 1 can detect the magnetic composition 9 when the magnetic field vector B changes over time, for example, as the magnetic composition 9 moves within the human body. Specifically, for example, when the magnetic composition 9 moves within the human body in response to peristaltic movement (about 0.05 Hz) of the stomach after being orally administered, the magnetic field vector B changes over time. Therefore, the detection device 1 can appropriately detect that the magnetic composition 9 is in the stomach based on the change over time of the magnetic field vector B.
[0094] The detection device 1 has three-dimensional magnetic sensors 51 to 54 attached to different positions on the human body. When it is determined that the angle φ(N) is greater than the angle threshold θth (S71: YES), the absolute value of the N-th difference vector ΔA(N) is greater than the magnitude threshold Mth (S73: YES), and the value |R(N)| is greater than 0.02 rad (S77: YES) for at least any of the three-dimensional magnetic sensors 51 to 54, the detection device 1 detects that the magnetic composition 9 is present within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S79). In this case, the detection device 1 can accurately detect the magnetic composition 9 from a wide area of the human body by attaching the three-dimensional magnetic sensors 51 to 54 to a wide area of the human body. In addition, the detection device 1 can more accurately identify the position of the human body where the magnetic composition 9 is present.
[0095] The detection device 1 includes an acceleration sensor 7. The detection device 1 determines whether the positional fluctuation of the human body is small based on the output result of the acceleration sensor 7 (S31). When the detection device 1 determines that the positional fluctuation of the human body is small (S31: YES), it measures the magnetic field vector B and detects the magnetic composition 9. In this case, the detection device 1 can measure the magnetic field vector B and detect the magnetic composition 9 when the human body is in a calm state. Therefore, the detection device 1 can minimize the effect of the positional fluctuation of the human body on the measurement result, and can accurately detect the magnetic composition 9 inside the human body.
[0096] <Special Notes on the Second Embodiment> The CPU 21 performing the processing of S35 is an example of the "acquiring means" of the present invention. The CPU 21 performing the processing of S41 is an example of the "average calculating means" of the present invention. The CPU 21 performing the processing of S79 is an example of the "detecting means" of the present invention. The CPU 21 performing the processing of S93 is an example of the "determining means" of the present invention.
[0097] <Magnetic composition 9> The magnetic composition 9 is orally administered into the human body and detected by the detection device 1. The magnetic composition 9 may be composed of only a magnetic material, or may contain components other than the magnetic material. That is, the magnetic composition 9 may contain at least one or more components (hereinafter referred to as "drug substances, etc.") among drug substances, enteric substances, poorly water-soluble substances, oils and fats, lubricants, etc. The magnetic composition 9 can also be in a form that is easy to administer orally. For example, when the magnetic composition 9 is composed of multiple components, these components can be mixed and compressed to form a solid tablet. The shape of the magnetic composition 9 may be a compressed tablet, a dry-coated tablet, a multi-layer tablet, etc. A dry-coated tablet has a core containing at least a magnetic material, and is formed by attaching a drug substance to the periphery of the core. A multi-layer tablet is formed by layering a drug substance, etc. on a core containing at least a magnetic material.
[0098] The medicinal substance is a medical drug for diagnosing, treating, and preventing diseases in the human body by being orally administered. The medicinal substance is prepared as a drug according to the purpose of use. The enteric substance is a substance that does not dissolve in the stomach but dissolves in the intestines. By adjusting the type and content of the enteric substance contained in the magnetic composition 9, the residence time of the orally administered magnetic composition 9 in the stomach can be adjusted. In this embodiment, a methacrylic acid polymer is used as the enteric substance. The poorly water-soluble substance is a substance that does not dissolve in the intestines. By adjusting the type and content of the poorly water-soluble substance contained in the magnetic composition 9, it is possible to adjust whether the orally administered magnetic composition 9 dissolves in the intestines. In this embodiment, ethyl cellulose is contained as the poorly water-soluble substance.
[0099] The oil repels moisture adhering to the magnetic composition 9 in the human body and inhibits the magnetic composition 9 from disintegrating in response to the penetration of moisture into the magnetic composition 9. In this embodiment, hardened oil is used as the oil. The lubricant inhibits the raw materials of the magnetic composition 9 from adhering to a molding device when molding the magnetic composition 9 into a tablet. In this embodiment, magnesium stearate is used as the lubricant. The magnetic material is a magnetic substance and contains at least iron oxide. In this embodiment, the magnetic material contains at least any one of maghemite, magnetite, and epsilon ferric oxide as the iron oxide.
[0100] The types and contents of each main component (enteric substance, poorly water-soluble substance, oils and fats, lubricants, etc.) are adjusted so that the magnetic composition 9 remains in the stomach for at least one hour after oral administration. This allows the detection device 1 to ensure the time required to detect the magnetic composition 9 remaining in the stomach, making it possible to easily and accurately detect the magnetic composition 9. In addition, the magnetic composition 9 may not disintegrate and may maintain its shape until it is excreted from the body.
[0101] <Example 2> The disintegration characteristics of the magnetic composition 9 in the stomach and intestines were evaluated. Maghemite (γ-MRD, manufactured by Titan Kogyo Co., Ltd.) was used as the magnetic material. Methacrylic acid copolymer LD (Eudragit L100-55, manufactured by Rehm Co., Ltd.) was used as the enteric material. Ethyl cellulose (Ethocel 10FP, manufactured by Dow Chemical Co., Ltd.) was used as the poorly water-soluble material. Hardened oil (Lubriwax 101, manufactured by Freund Corporation) was used as the oil and fat. Magnesium stearate (manufactured by Mallinckrodt Co., Ltd.) was used as the lubricant. These were formulated to obtain the amounts (unit: g) shown in Experiments 1 to 13 in FIG. 9, and tablets were prepared. The proportions of the amounts of the ingredients were allocated according to the Box-Behnken experimental design method.
[0102] Each material except magnesium stearate was weighed and mixed in a mortar. Then, 1 mL of ethanol (Kanto Chemical) was added, and the powder was wet-kneaded in the mortar. The kneaded powder was dried overnight at 60°C in a tray dryer, and then sized using a sieve with 1 mm openings. Next, magnesium stearate was added to the sized granules and mixed. The mixed powder was weighed to about 50 mg and compressed with a single punch tablet press (Okada Seiko Co., Ltd., Tabflex) at a force of 5 kN. This resulted in tablets with a diameter of 4.8 mm. The tablets had a hardness of 20 N or more (see Figure 10).
[0103] The dissolution characteristics of the tablets were evaluated using a dissolution tester (NTR-6300, Toyama Sangyo Co., Ltd.) as follows. After the weight of the tablet was measured, the tablet was placed in a vessel containing 900 mL of 0.1 mol / L hydrochloric acid simulating gastric fluid or pH 6.8 phosphate buffer simulating intestinal fluid, and stirred for 2 hours at a paddle rotation speed of 50 rpm and a test liquid temperature of 37°C. After stirring for 2 hours, the tablet was taken out and dried overnight at 60°C in a tray dryer, and the weight of the tablet after the test was measured. The results are shown in Figure 10.
[0104] As shown in Figure 10, the weight loss rate in 0.1 mol / L hydrochloric acid was about 1% for all tablets, indicating that the tablets hardly disintegrate in gastric acid. On the other hand, the weight loss rate in pH 6.8 phosphate buffer solution was found to vary significantly depending on the tablet. This indicates that the disintegration characteristics in the intestine can be adjusted as desired by changing the amount of each ingredient added.
[0105] <Example 3> The disintegration characteristics of the magnetic composition 9 in the intestine were evaluated. Methacrylic acid copolymer LD (Eudragit L100-55, manufactured by Rehm Co., Ltd.) was used as the enteric substance. Ethyl cellulose (Ethocel 10FP, manufactured by Dow Chemical Co., Ltd.) was used as the poorly water-soluble substance. The weight loss rate (%) in a pH 6.8 phosphate buffer solution was estimated by multiple regression analysis.
[0106] Fig. 11(A) shows the weight loss rate of the magnetic composition 9 when 5% hardened oil is included as fat and oil, and the ratio of the amount of methacrylic acid copolymer LD and ethyl cellulose is adjusted. Fig. 11(B) shows the weight loss rate of the magnetic composition 9 when no fat and oil is included, and the ratio of the amount of methacrylic acid copolymer LD and ethyl cellulose is adjusted.
[0107] As shown in Fig. 11, it was found that the degradation of the magnetic composition 9 in the intestines can be suppressed by decreasing the methacrylic acid copolymer LD or increasing the ethyl cellulose. It was also found that the degradation of the magnetic composition 9 in the intestines can be suppressed by adding fats and oils.
[0108] <Example 4> The dissolution characteristics of the magnetic composition 9 in the body were further evaluated. Maghemite (γ-MRD, manufactured by Titan Kogyo Co., Ltd.) was used as the magnetic material. Ammonioalkyl methacrylate copolymer (Eudragit RS, manufactured by Rehm Co., Ltd.) was used as the enteric material. Ethyl cellulose (Ethycel 10FP, manufactured by Dow Chemical Co., Ltd.) was used as the poorly water-soluble material. Hardened oil (Lubriwax 101, manufactured by Freund Corporation) was used as the oil. Ethanol (manufactured by Kanto Chemical Co., Ltd.) was used as the solvent. Magnesium stearate (manufactured by Mallinckrodt Co., Ltd.) was used as the lubricant. These were formulated to obtain the amounts (unit: g) shown in FIG. 12, and tablets were prepared.
[0109] Maghemite, ammonioalkyl methacrylate copolymer, ethyl cellulose, and hardened oil were each added to a 1L Super Mixer (Kawata Co., Ltd.), and mixed for 3 minutes at a blade rotation speed of 1400 rpm. Next, ethanol was added while rotating the blade at 1400 rpm, and granulation was carried out for 3 minutes. The granules obtained by granulation were dried overnight at 60°C using a shelf dryer. Then, disintegration and sizing were carried out using a Power Mill (Dalton Co., Ltd.) with a screen mesh size of 1.0 mm and a blade rotation speed of 5000 rpm. Magnesium stearate was added to the granules, and lubricated and mixed in a plastic bag.
[0110] The granules were compressed using a rotary tablet press (VIRGO, Kikusui Seisakusho) at a turntable speed of 30 rpm and a compression pressure of 10 kN, resulting in tablets with a diameter of 6 mm and a weight of 120 mg.
[0111] The dissolution characteristics of the tablets obtained as described above were evaluated. The evaluation of the dissolution characteristics was performed using a dissolution tester (NTR-6300, Toyama Sangyo Co., Ltd.). After the weight of the tablets was measured, they were placed in a vessel containing 900 mL of 0.1 mol / L hydrochloric acid, which is a test liquid simulating gastric fluid, or a phosphate buffer solution of pH 6.8, which is a test liquid simulating intestinal fluid. Then, the tablets were stirred for 24 hours at a paddle rotation speed of 50 rpm and a test liquid temperature of 37°C. After stirring for 24 hours, the tablets were taken out and dried overnight at 60°C using a tray dryer. Then, the weight of the tablets was measured.
[0112] As shown in Figure 13, the weight change rate in both 0.1 mol / L hydrochloric acid and pH 6.8 phosphate buffer was 1% or less. This shows that by preparing the tablets as described above, it is possible to obtain tablets that do not disintegrate in the digestive tract of the human body and can be excreted in feces as is.
[0113] <Example 5> The dissolution characteristics of the magnetic composition 9 in the body were evaluated by confirming whether tablets administered to beagles disintegrated. The tablets used were those obtained in Example 4. The tablets were magnetized with a neodymium magnet, and then packed in gelatin capsules of size 000, ten tablets each. Two capsules (20 tablets) were then orally administered to each of three beagles. After oral administration, feces were periodically collected, and the tablets excreted in the feces were recovered.
[0114] As shown in Figure 14, all 20 tablets orally administered were recovered in all beagle dogs. In addition, when comparing the masses before and after oral administration, the change was about 2% or less in all beagle dogs, and no significant difference was observed. In addition, as shown in Figure 15, there was no significant difference in appearance between the tablets excreted at 23 hours and the tablets excreted at 48 hours. The photographs in Figure 15 show representative examples of tablets excreted at each time. From this, it was inferred that the tablets would not disintegrate even if their retention time in the digestive tract was somewhat longer due to constipation, etc.
[0115] <Example 6> The preparation method of magnetic composition 9 was evaluated. Maghemite as a magnetic material, methacrylic acid copolymer LD as an enteric material, ethyl cellulose as a poorly water-soluble material, and hardened oil as fats and oils were each charged into a 100L Super Mixer (Kawata Co., Ltd.). The same products as those in Example 2 were used for each. Mixing was performed for 3 minutes at a blade rotation speed of 460 rpm. Next, ethanol was charged while rotating the blade at 460 rpm, and granulation was performed for 3 minutes. The granules obtained by granulation were dried overnight at 60°C using a shelf dryer. Then, crushing and sizing were performed using a power mill (Dalton Co., Ltd.) with a screen mesh size of 1.0 mm and a blade rotation speed of 2000 rpm. Magnesium stearate was added as a lubricant to the granules, and they were mixed in a plastic bag. The amount of each material charged is shown in FIG. 16.
[0116] The granules were compressed using a rotary tablet press (AQUA3, Kikusui Seisakusho) at a turntable speed of 40 rpm and a compression pressure of 13.5 kN, yielding tablets with a diameter of 6 mm and a weight of 140 mg.
[0117] <Example 7> The method of molding the magnetic composition 9 into a dry-coated tablet was evaluated. Spray-dried lactose (Supertab 11SD, DMV), low-substituted hydroxypropylcellulose (LH-21, Shin-Etsu Chemical), and magnesium stearate (Mallinckrodt) were mixed in a plastic bag to prepare an outer layer powder corresponding to the drug substance. The amount of each material charged is shown in FIG. 17. Using this outer layer powder and the tablet obtained in Example 6, the tablet was molded using a rotary tablet press (AQUA-LD, Kikusui Seisakusho) at a turntable rotation speed of 15 rpm and a compression pressure of 22 kN. This resulted in a dry-coated tablet in which the drug substance or the like was attached around the core containing at least the magnetic material. The weight of the outer layer powder was 270 mg. The diameter of the dry-coated tablet was 9 mm and the weight was 410 mg.
[0118] <Example 8> A method of molding the magnetic composition 9 into a multi-layer tablet was evaluated. The granules (weight 140 mg) used in the process of obtaining the tablets in Example 6 and the outer layer powder (weight 270 mg) prepared in Example 7 were used and molded with a rotary tablet press (AQUA-LD, manufactured by Kikusui Seisakusho) at a turntable rotation speed of 15 rpm and a compression pressure of 8 kN. This resulted in a multi-layer tablet in which a drug substance and the like were layered on the surface of a core containing at least a magnetic material. The multi-layer tablet had a diameter of 9 mm and a weight of 410 mg. <Example 9> The preparation method of magnetic composition 9 is evaluated. Maghemite as a magnetic material, methacrylic acid copolymer LD as an enteric material, ethyl cellulose as a poorly water-soluble material, hardened oil as an oil and fat, and a medicinal substance are each charged into a 100L super mixer (manufactured by Kawata Co., Ltd.). The same products as those in Example 2 are used for each. Mixing is performed for 3 minutes at a blade rotation speed of 460 rpm. Next, ethanol is charged while rotating the blade at 460 rpm, and granulation is performed for 3 minutes. The granules obtained by granulation are dried overnight at 60°C using a shelf dryer. Then, crushing and sizing are performed using a power mill (manufactured by Dalton Co., Ltd.) with a screen mesh size of 1.0 mm and a blade rotation speed of 2000 rpm. Magnesium stearate is added as a lubricant to the granules, and they are mixed in a plastic bag.
[0119] The granules are compressed into tablets with a rotary tablet press (AQUA3, Kikusui Seisakusho) at a turntable speed of 40 rpm and a compression pressure of 13.5 kN, resulting in tablets with a diameter of 6 mm and a weight of 140 mg.
[0120] <Example 10> The detection possibility of the magnetic composition 9 by the detection device 1 was evaluated. As a tablet with a slow dissolution rate, the tablet obtained in Example 6 (referred to as the first tablet) was used. A tablet with a fast dissolution rate was molded by the following method. Spray-dried lactose (Supertab 11SD, manufactured by DMV), low-substituted hydroxypropyl cellulose (LH-21, manufactured by Shin-Etsu Chemical), maghemite (γ-MRD, manufactured by Titanium Kogyo Co., Ltd.), and magnesium stearate (manufactured by Mallinckrodt Co., Ltd.) were weighed in the amounts shown in FIG. 18 and mixed in a mortar. Then, about 240 mg of the mixed powder was weighed and molded using a single punch tablet press (manufactured by Okada Seiko Co., Ltd., Tabflex) at a compression pressure of 10 kN to obtain a tablet with a diameter of 8 mm. This tablet was magnetized by a neodymium magnet. Hereinafter, this tablet is referred to as the second tablet. The first tablet and the second tablet are collectively referred to as sample tablets.
[0121] To simulate the magnetic signal from inside the human stomach when a sample tablet is orally administered, an MI sensor was attached to a dissolution tester (NTR-6300, manufactured by Toyama Sangyo). The sample tablet was placed in 0.1 mol / L hydrochloric acid (called the dissolution test solution) and stirred, and the magnetic flux density of the magnetic signal detected was measured by the MI sensor. The distance from the tablet to the MI sensor was approximately 15 cm. Stirring was performed using a rotating basket at a rotation speed of 200 rpm.
[0122] The graph in FIG. 19(A) shows the magnetic flux density of the magnetic signal detected in the absence of a sample tablet. The graph in FIG. 19(B) shows the magnetic flux density immediately after the second tablet is added to the dissolution test liquid. The graph in FIG. 19(C) shows the magnetic flux density immediately after the first tablet is added to the dissolution test liquid. The graph in FIG. 19(D) shows the magnetic flux density 1 hour after the first tablet is added to the dissolution test liquid. The graph in FIG. 19(E) shows the magnetic flux density 2 hours after the first tablet is added to the dissolution test liquid. The graph in FIG. 19(F) shows the magnetic flux density 4 hours after the first tablet is added to the dissolution test liquid.
[0123] From the results in Figure 19(B), it was found that the second tablet disintegrated quickly when placed in the dissolution test solution, and the magnetic signal disappeared within a few seconds. On the other hand, as shown in Figures 19(C) to (F), the first tablet did not disintegrate even after 4 hours, and the magnetic signal was maintained.
[0124] <Example 11> The detectability of the magnetic composition 9 was evaluated. Three-dimensional magnetic sensors 5 (X-axis sensor, Y-axis sensor, Z-axis sensor) were attached to two locations, the anterior abdomen and the flank abdomen, of the human body. Magnetic signals were detected by the X-axis sensor, the Y-axis sensor, and the Z-axis sensor, respectively, before and after the tablet obtained in Example 2 was orally administered, and the magnetic flux density was measured. A bandpass filter was applied to the measurement results, and the frequency component of the peristaltic movement of the stomach (0.05 Hz ± 0.03 Hz) was extracted.
[0125] FIG. 20 shows the measurement results of the X-axis sensor, the Y-axis sensor, and the Z-axis sensor attached to two locations on the human body (front and flank) when a tablet has not been orally administered. The horizontal axis indicates time (seconds), and the vertical axis indicates magnetic flux density (nT). (A) shows the measurement result two hours after lunch. (B) shows the measurement result before dinner. (C) shows the measurement result after dinner. FIG. 21 shows the measurement results of the X-axis sensor, the Y-axis sensor, and the Z-axis sensor attached to two locations on the human body (front and flank) when a tablet has been orally administered. The horizontal axis indicates time (seconds), and the vertical axis indicates magnetic flux density (nT). (A) shows the measurement result immediately after the tablet has been administered. (B) shows the measurement result two hours after the tablet has been administered. (C) shows the measurement result four hours after the tablet has been administered.
[0126] From the measurement results from when the tablet was not administered until immediately after it was administered (Figures 20(A)-(C), Figure 21(A)), it was found that almost no magnetic signal was detected during this period. On the other hand, from the measurement results 2 hours and 4 hours after the tablet was administered (see Figures 21(B)(C)), a magnetic signal was detected during these periods, and periodic changes in magnetic flux density were confirmed. From the above, it was found that the above method can produce tablets that can be detected by the detection device 1.
[0127] <Example 12> The relationship between the amount of magnetic material added to the magnetic composition 9 and the magnetic flux density was evaluated. The granules used in the process of obtaining the tablets in Example 6 were weighed and compressed by a single punch tableting machine (Tabflex, manufactured by Okada Seiko Co., Ltd.). As a result, a third tablet with a granule weight of about 26 mg, a fourth tablet with a granule weight of 52 mg, and a fifth tablet with a granule weight of 129 mg were obtained. The third tablet had a diameter of 3.5 mm and contained about 20 mg of maghemite. The third tablet was molded at a compression pressure of 3 kN. The fourth tablet had a diameter of 5 mm and contained about 40 mg of maghemite. The fourth tablet was molded at a compression pressure of 5 kN. The fifth tablet had a diameter of 6 mm and contained about 100 mg of maghemite. The fifth tablet was molded at 10 kN. The third to fifth tablets were magnetized with a neodymium magnet. The magnetic flux density at positions 10 cm, 15 cm, and 20 cm away from each tablet was measured using an MI sensor.
[0128] As shown in Fig. 22, it was found that the measured magnetic flux density increases as the content of maghemite increases. It was also found that the relationship between the content of maghemite and the magnetic flux density is approximately linear. It was also confirmed that the magnetic flux density measured by the MI sensor increases as the distance between the tablet and the three-dimensional magnetic sensor 5 becomes closer.
[0129] <Actions and Effects of Magnetic Composition 9> The magnetic composition 9 is enteric or poorly water-soluble, and after being orally administered, it remains in the stomach for at least one hour. In this case, the detection device 1 only needs to intermittently measure the magnetic field vector B using the three-dimensional magnetic sensor 5 during the period in which the magnetic composition 9 remains in the stomach, and the processing load in the detection device 1 can be reduced, thereby making it possible to reduce the power consumption of the detection device 1.
[0130] The magnetic composition 9 can be prepared so as to be discharged without disintegrating in the body. In this case, even if the change in the magnetic vector output from the magnetic composition 9 in the stomach due to peristalsis is an extremely low frequency (about 0.05 Hz, a period of about once every 20 seconds), the magnetic composition 9 can be detected by measuring the magnetic vector with the three-dimensional magnetic sensor 5. Therefore, the detection accuracy of the magnetic composition 9 can be improved.
[0131] Furthermore, by insolubilizing the magnetic composition 9, the influence of magnetic attenuation due to disintegration can be suppressed. Furthermore, since the time that the magnetic composition 9 remains in the stomach can be extended, the detection device 1 can stably measure the magnetic vector over a long period of time using the three-dimensional magnetic sensor 5. Furthermore, since the measurement cycle of the three-dimensional magnetic sensor 5 can be set to a long period of time, power saving is possible, and the frequency of battery replacement can be reduced.
[0132] The magnetic composition 9 contains iron oxide as a magnetic material. More specifically, the magnetic composition 9 contains at least one of maghemite, magnetite, and epsilon iron oxide as the iron oxide. In this case, the measurement of the magnetic field vector B by the three-dimensional magnetic sensor 5 in the detection device 1 can be performed with high accuracy. In addition, the magnetic composition 9 contains an enteric substance. In this case, the magnetic composition 9 can be prepared so that the behavior of the magnetic composition 9 in the stomach is as desired. In addition, the magnetic composition 9 contains a poorly water-soluble substance. In this case, the magnetic composition 9 can be prepared so that the behavior of the magnetic composition 9 in the intestine is as desired. Furthermore, the magnetic composition 9 contains oils and fats. In this case, the degree to which the magnetic composition 9 absorbs liquid can be reduced, so that the magnetic composition 9 is less likely to disintegrate. Therefore, the magnetic composition 9 can be appropriately retained in the human body.
[0133] The magnetic composition 9 contains a magnetic material, but it can also be in the form of a dry-coated tablet in which a medicinal substance is attached around a core of the magnetic material, or a multi-layer tablet in which the magnetic material is layered. Furthermore, the magnetic composition 9 can be encapsulated together with other components such as medicinal substances in a capsule for oral administration. In these cases, the magnetic composition 9 can be easily administered orally to the human body as a pharmaceutical composition.
[0134] According to the present invention, the orally administered composition or the drug substance contained in the orally administered composition can be administered by detecting the magnetic composition 9 contained in an orally administered composition (pharmaceutical composition) containing a drug substance with the detection device 1. Specifically, after taking the orally administered composition containing the magnetic composition 9, the magnetic composition 9 is detected with the detection device 1 with respect to the swallowing of the orally administered composition, its passage through the esophagus, and its movement in the stomach and intestines, thereby enabling administration of the orally administered composition or the drug substance contained in the orally administered composition.
[0135] <Modification> The present invention is not limited to the above-described first and second embodiments, and various modifications are possible. In the present embodiment, the detection device 1 has three-dimensional magnetic sensors 51 to 54. The number of three-dimensional magnetic sensors 5 that the detection device 1 has is not limited. For example, the detection device 1 may have only one three-dimensional magnetic sensor 5.
[0136] In the first embodiment, when it is determined that |B'| is 50 nT or more (S19: YES) and the value |R'| is greater than 0.02 rad (S21: YES), the detection device 1 detects that the magnetic composition 9 is present within the detection range 50A of the three-dimensional magnetic sensor 5 (S23). In contrast, the presence of the magnetic composition 9 may be detected by performing a determination only based on the value |R'| without making a determination based on |B'|. The detection device 1 may also detect the presence of the magnetic composition 9 by directly comparing the change over time θ' of the angle θ of the magnetic field vector B with a predetermined threshold value. Furthermore, the detection device 1 may detect the magnetic composition 9 based on the change over time of the magnitude |B| of the magnetic field vector B, rather than the change over time θ' of the angle θ of the magnetic field vector B.
[0137] In the second embodiment, when it is determined that the angle φ(N) is greater than the angle threshold θth (S71: YES), the absolute value |ΔA(N)| of the Nth difference vector ΔA(N) is greater than the magnitude threshold Mth (S73: YES), and the value |R(N)| is greater than 0.02 rad (S77: YES), the detection device 1 detects that the magnetic composition 9 is present within the detection range 50A of the three-dimensional magnetic sensor 5 (S79). In contrast, it is not necessary to make a determination based on either the angle φ(N) or the absolute value |ΔA(N)|. Furthermore, the presence of the magnetic composition 9 may be detected by making a determination only based on the value |R(N)| without making a determination based on the angle φ(N) and the absolute value |ΔA(N)|.
[0138] In the second embodiment, the detection device 1 may determine whether or not the magnetic composition 9 is present based on the magnitude relationship between the angle (hereinafter referred to as the first angle) between the Nth average vector A(N) and the N+1th average vector A(N+1) and a predetermined threshold value. For example, the CPU 21 may calculate an angle φ(N) by subtracting π / 2 [rad] from the first angle (S49), and when the angle φ(N) is equal to or smaller than the angle threshold value θth (S71: NO), calculate a value R(N) based on the angle φ(N) calculated from the first angle (S75). When the absolute value |R(N)| of the value R(N) is equal to or larger than 0.02 rad (S77: YES), the CPU 21 may determine that the magnetic composition 9 is present in the human body at a position within the detection range 50A of the corresponding three-dimensional magnetic sensor 5 (S79).
[0139] The CPU 21 may detect the magnetic composition 9 in the human body based on the first angle or the value R(N) obtained by dividing the first angle by the magnitude |ΔA(N)| of the difference vector. FIG. 23 is a graph showing the value R(N) obtained by dividing the first angle by the magnitude |ΔA(N)| of the difference vector. The horizontal axis shows time (seconds), and the vertical axis shows the value R(N). FIG. 23 shows the results of an experiment conducted on an obese subject. FIGS. 23(A)-(C) show the results before the magnetic composition 9 was orally administered, and FIGS. 23(D)-(F) show the results after the magnetic composition 9 was taken. FIGS. 23(A) and 23(D) show the results when the predetermined time T for calculating the average vector A is set to 0.5 s. FIGS. 23(B) and 23(E) show the results when the predetermined time T is set to 1.0 s. 23(C) and 23(F) show the results when the predetermined time T was set to 2.0 s. As shown in Fig. 23, even when the value R(N) was calculated using the first angle instead of the second angle, it was found that the degree of change before and after oral administration became clear.
[0140] In the second embodiment, the CPU 21 may calculate R(N) by dividing θ(N) by the absolute value |ΔA(N)|. Furthermore, the CPU 21 may calculate R(N) by dividing the above-mentioned first angle by the absolute value |ΔA(N)|. When the absolute value |R(N)| of the value R(N) is 0.02 rad or more (S77: YES), the CPU 21 may determine that the magnetic composition 9 is present in the human body at a position within the detection range 50A of the corresponding three-dimensional magnetic sensor 5.
[0141] The detection device 1 may filter the measurement results acquired from the three-dimensional magnetic sensor 5 using a band-pass filter capable of extracting the frequency of stomach peristalsis of 0.05 Hz. The detection device 1 may detect the magnetic composition 9 based on the results obtained by filtering. The detection device 1 may not include the acceleration sensor 7. The detection device 1 may detect the magnetic composition 9 regardless of the state of positional fluctuation of the human body.
[0142] In the determination process (see FIG. 8), the CPU 21 may acquire the speed of the human body movement via the input unit 24. A table associating the speed of the human body movement with the predetermined time T may be stored in advance in the storage unit 22. The CPU 21 may determine the predetermined time T corresponding to the acquired speed by referring to the table. The CPU 21 may update the predetermined time T stored in the storage unit 22 to the determined predetermined time T.
[0143] In the second main process, the CPU 21 may acquire voltage signals output by the three-dimensional magnetic sensors 51-54 continuously for a certain period of time, and identify the magnetic field vector B (Bx, By, Bz) measured by each of the three-dimensional magnetic sensors 51-54 (S33). The CPU 21 may store the identified magnetic field vector B in the storage unit 22 (S35). After the certain period of time has elapsed, the CPU 21 may acquire the magnetic field vector B stored in the storage unit 22 for each predetermined time T determined by the determination process (see FIG. 8) (S39), and execute the processes of S41 to S53. For example, the CPU 21 may determine a plurality of predetermined times T by the determination process, acquire the magnetic field vector B stored in the storage unit 22 for each of the determined predetermined times T (S39), and execute the processes of S41 to S53.
[0144] The residence time of the magnetic composition 9 in the stomach may be less than 1 hour. The magnetic composition 9 may include at least one of an enteric substance and a poorly water-soluble substance, without including the other. The magnetic composition 9 may not include both an enteric substance and a poorly water-soluble substance. The magnetic composition 9 may not include fats or oils. The materials contained in the magnetic composition 9 as the enteric substance, poorly water-soluble substance, and fats and oils are not limited to this embodiment, and may be other materials.
[0145] The magnetic composition 9 may contain, as iron oxide, a material that is a combination of two or more materials selected from maghemite, magnetite, and epsilon iron oxide. The iron oxide is not limited to maghemite, magnetite, and epsilon iron oxide, but may be other materials. The material contained as a magnetic material in the magnetic composition 9 is not limited to iron oxide, but may be other magnetic materials.
[0146] In the magnetic composition 9, the core of the dry-coated tablet or multi-layered tablet may be formed only from a magnetic material. The magnetic composition 9 may be molded into a shape other than a dry-coated tablet or a multi-layered tablet. For example, the magnetic composition 9 may be molded by encapsulating each material in a capsule. [Explanation of symbols]
[0147] 1: Detection device 5: 3D magnetic sensor 7: Acceleration sensor 9: Magnetic composition 21: CPU 51, 52, 53, 54: 3D magnetic sensor
Claims
1. A detection device for detecting a magnetic composition that is orally administered to a human body and contains a magnetic substance, At least one three-dimensional magnetic sensor that measures a magnetic field vector formed by the magnetic body contained in the magnetic composition by arranging magnetic sensors having directional anisotropy in at least three different directions; an acquisition means for acquiring the magnetic field vector measured by the three-dimensional magnetic sensor; a detection means for detecting the magnetic composition within the human body by detecting whether the magnetic composition is present at a position within a detection range of one of the three-dimensional magnetic sensors based on the magnetic field vector acquired by the acquisition means from one of the three-dimensional magnetic sensors; Equipped with The acquisition means includes: Obtaining a time change in the angle of the magnetic field vector; The detection means includes: A detection device characterized by detecting the presence of the magnetic composition at a position within the detection range of the three-dimensional magnetic sensor based on the relationship between the time change in angle of the magnetic field vector acquired by the acquisition means, or the value obtained by dividing the time change in angle by the magnitude of the time change of the magnetic field vector, and a predetermined amount corresponding to the period of peristaltic movement.
2. a plurality of the three-dimensional magnetic sensors each attached to a different position on a human body; The detection means includes: The detection device described in claim 1, characterized in that it detects that the magnetic composition is present within the detection range of one of the multiple three-dimensional magnetic sensors, where the change in angle of the magnetic field vector acquired by the acquisition means over time, or the value obtained by dividing the change in angle over time by the magnitude of the change in the magnetic field vector over time, is greater than the predetermined amount.
3. A detection device that is orally administered to a human body and detects a magnetic composition containing a magnetic material, At least one three-dimensional magnetic sensor that measures a magnetic field vector formed by the magnetic body contained in the magnetic composition by arranging magnetic sensors having directional anisotropy in at least three different directions; an acquisition means for acquiring the magnetic field vector measured by the three-dimensional magnetic sensor; a detection means for detecting the magnetic composition within the human body by detecting whether the magnetic composition is present at a position within a detection range of one of the three-dimensional magnetic sensors based on the magnetic field vector acquired by the acquisition means from one of the three-dimensional magnetic sensors; Equipped with The acquisition means includes: The magnetic field vector measured by the three-dimensional magnetic sensor is acquired in each of M periods (M is an integer equal to or greater than 2) that are a plurality of periods divided by a predetermined time, The method further includes an average calculation means for calculating an average of the magnetic field vectors acquired by the acquisition means for each of the M time periods as an average vector, The detection means includes: The detection device described in the above is characterized in that the presence of the magnetic composition within the detection range of the three-dimensional magnetic sensor is detected based on a relationship between a first angle between an N-th average vector, which is the average vector of the magnetic field vectors acquired in an N-th period, which is the N-th period (N is an integer greater than or equal to 1 and less than or equal to M-1) in the order of the M periods when arranged in chronological order, among the M average vectors calculated by the average calculation means, and an N+1-th average vector, which is the average vector of the magnetic field vectors acquired in an N+1-th period, which is the N+1-th period corresponding to the next period whose order is Nth when the M periods are arranged in chronological order, a second angle between the difference vector between the N-th average vector and the N+1 vector and the N-th average vector, and a division value obtained by dividing the first angle or the second angle by the magnitude of the difference vector, and a predetermined condition corresponding to the period of peristalsis.
4. A determination means for determining the predetermined time, The average calculation means 4. The detection device according to claim 3, wherein an average of the magnetic field vectors acquired by the acquisition means for each of the predetermined time periods determined by the determination means is calculated as an average vector.
5. 5. The detection device according to claim 3, wherein the magnetic sensor outputs a voltage proportional to a measured magnetic field.
6. An acceleration sensor; a determination means for determining whether a state of a position change of the human body satisfies a predetermined condition based on an output result of the acceleration sensor; Equipped with The acquisition means includes:
6. The detection device according to claim 1, wherein the magnetic field vector is acquired when the determining means determines that the state of the positional variation satisfies the predetermined condition.
7. 1. A management system for managing the administration of a pharmaceutical substance, comprising a magnetic composition and a detection device, The detection device includes: A detection device for detecting the magnetic composition, which is orally administered to a human body and contains a magnetic material, comprising: At least one three-dimensional magnetic sensor that measures a magnetic field vector formed by the magnetic body contained in the magnetic composition by arranging magnetic sensors having directional anisotropy in at least three different directions; an acquisition means for acquiring the magnetic field vector measured by the three-dimensional magnetic sensor; a detection means for detecting the magnetic composition within the human body by detecting whether the magnetic composition is present at a position within a detection range of one of the three-dimensional magnetic sensors based on the magnetic field vector acquired by the acquisition means from one of the three-dimensional magnetic sensors; Equipped with The acquisition means includes: Obtaining a time change in the angle of the magnetic field vector; The detection means includes: detects the presence of the magnetic composition at a position within a detection range of the three-dimensional magnetic sensor based on a relationship between a time change in the angle of the magnetic field vector acquired by the acquisition means, or a value obtained by dividing the time change in the angle by the magnitude of the time change in the magnetic field vector, and a predetermined amount corresponding to a period of peristaltic movement; The magnetic composition comprises: The drug is orally administered to the human body, contains at least the magnetic material, and is detected by a detection device.
1. A management system comprising:
8. A management system for managing the administration of a pharmaceutical substance, comprising a magnetic composition and a detection device, The detection device includes: A detection device for detecting the magnetic composition, which is orally administered to a human body and contains a magnetic material, comprising: At least one three-dimensional magnetic sensor that measures a magnetic field vector formed by the magnetic body contained in the magnetic composition by arranging magnetic sensors having directional anisotropy in at least three different directions; an acquisition means for acquiring the magnetic field vector measured by the three-dimensional magnetic sensor; a detection means for detecting the magnetic composition within the human body by detecting whether the magnetic composition is present at a position within a detection range of one of the three-dimensional magnetic sensors based on the magnetic field vector acquired by the acquisition means from one of the three-dimensional magnetic sensors; Equipped with The acquisition means includes: The magnetic field vector measured by the three-dimensional magnetic sensor is acquired in each of M periods (M is an integer equal to or greater than 2) that are a plurality of periods divided by a predetermined time, The method further includes an average calculation means for calculating an average of the magnetic field vectors acquired by the acquisition means for each of the M time periods as an average vector, The detection means includes: the presence of the magnetic composition within a detection range of the three-dimensional magnetic sensor is detected based on a relationship between a target parameter that is at least any one of a first angle between an Nth average vector, which is the average vector of the magnetic field vectors acquired in an Nth period, which is the Nth period (N is an integer between 1 and M-1) in order when the M periods are arranged in a chronological order among the M average vectors calculated by the average calculation means, and an N+1th average vector, which is the average vector of the magnetic field vectors acquired in an N+1th period, which is the N+1th period corresponding to the next period whose order is Nth when the M periods are arranged in a chronological order, a second angle between a difference vector between the Nth average vector and the N+1 vector and the Nth average vector, and a division value obtained by dividing the first angle or the second angle by the magnitude of the difference vector, and a predetermined condition corresponding to a period of peristaltic movement; The magnetic composition comprises: The drug is orally administered to the human body, contains at least the magnetic material, and is detected by a detection device.
1. A management system comprising:
Citation Information
Patent Citations
Oral drug compliance monitoring using magnetic field sensors
JP2009535103A
Ferrofluids and their therapeutic uses
JP2009537567A
Biological information measuring device and biological information measuring system
JP2014217707A
Detection system for detecting magnetic substances in the human body
JP2015500715A
Personalized detection system for detecting magnetic substances in the human body
JP2016528947A
